ESR1 and neoplasm: Our earlier report revealed very marked heterogeneity between resistant tumours in key IHC biomarkers.12 Of note, ER expression was maintained or enhanced in the majority of tumours and was felt to be consistent with a potential for oestrogen signalling in the face of AI to be a driver of resistance, a mechanism that is supported in only a minority of ER + resistant tumours in the current study.